top of page

How to Choose a Probiotic Blend Manufacturer for Bulk Supplement Production

7 days ago
22 min read

The global probiotic industry is creating new opportunities for nutraceutical companies, dietary supplement manufacturers, functional food businesses, and private-label brands. Businesses are increasingly exploring probiotic formulations for gut health, general wellness, women's health, healthy ageing, and other applications.

However, developing a successful probiotic supplement requires more than selecting bacterial strains and combining them into a powder. Manufacturers must consider strain identity, scientific evidence, safety, compatibility, viable cell counts, formulation stability, production processes, packaging, shelf life, quality assurance, and applicable regulatory requirements.

For companies planning bulk supplement production, choosing the right probiotic blend manufacturer is therefore a strategic business decision.

Scientific guidance emphasizes that probiotic microorganisms should be adequately characterized, safe for their intended use, supported by appropriate evidence, and present at an effective level throughout shelf life [1].

Understand Your Probiotic Product Requirements Before Selecting a Manufacturer

The first step is to define the product you intend to manufacture. Without a clear specification, it is difficult to compare suppliers or determine whether a proposed formulation is technically and commercially appropriate.

A manufacturer supplying a probiotic ingredient for a daily capsule supplement may have different capabilities from a manufacturer developing a multi-strain powder for sachets, a functional beverage, or a specialized nutrition product.

Before contacting potential suppliers, establish the following requirements.

Intended application

Identify the intended product category and consumer positioning. Possible applications include:

  • General digestive wellness supplements

  • Daily probiotic capsules

  • Multi-strain probiotic powders

  • Women's wellness formulations

  • Synbiotic products combining probiotics and prebiotics

  • Functional food and beverage ingredients

  • Sports and active-nutrition products

  • Healthy-ageing formulations

  • Specialized nutritional products

These categories should be treated as formulation objectives rather than proof that a particular probiotic produces a specific health outcome.

The evidence supporting probiotic benefits is not interchangeable across strains, formulations, or intended applications. A systematic review found that probiotic efficacy can vary according to both the strain and the condition being investigated [2].

Dosage form

Determine the intended finished dosage form before selecting the ingredient.

Common options include:

  • Hard-shell capsules

  • Tablets, where the formulation and process are suitable

  • Powder sachets

  • Stick packs

  • Bulk powder for subsequent encapsulation

  • Functional food applications

  • Selected beverage applications

  • Specialized nutritional formulations

Each dosage form creates different technical requirements. Moisture exposure, processing temperature, compression forces, oxygen exposure, and storage conditions can influence probiotic viability.

A supplier should therefore evaluate the intended dosage form rather than recommend the same ingredient specification for every application.

Target markets

Identify the countries in which the finished product will be marketed.

A formulation intended for the United States may require a different regulatory and documentation strategy from one intended for the European Union, the United Kingdom, the Gulf region, or other international markets.

Requirements may differ according to product classification, ingredient status, permissible claims, labeling rules, and local import requirements.

Key purchasing principle: Define the application, dosage form, target market, intended shelf life, and approximate annual volume before requesting quotations.

Lactobacillus rhamnosus probiotic powder for bulk probiotic blends
Strain-level identity, such as a specific Lactobacillus rhamnosus strain, should be documented by your manufacturer.

Evaluate the Manufacturer's Scientific and Technical Expertise

A probiotic blend manufacturer should offer more than the ability to combine ingredients. The supplier should understand the biological and technological characteristics of the microorganisms used in its formulations.

Strain-level identification

Probiotic microorganisms should be identified at an appropriate taxonomic level, including the strain designation where applicable.

For example, identifying an organism only as Lactobacillus rhamnosus does not provide the same level of information as identifying a specific strain within that species.

Strain identity matters because scientific evidence and certain functional characteristics may be associated with a particular strain rather than every member of a species. Expert guidance recommends adequate characterization of probiotic microorganisms, with strain-level identification forming an important part of the evaluation process [1].

Ask the manufacturer:

  • What is the complete strain designation?

  • How is strain identity established?

  • Is the strain maintained under controlled conditions?

  • Can the supplier provide relevant identity documentation?

  • Is the strain traceable to an authenticated reference or internal master culture?

  • Can the supplier explain the relationship between the selected strain and the proposed application?

A technically credible manufacturer should be able to answer these questions without relying exclusively on a species name or a marketing description.

Strain library and sourcing strategy

A broad strain library can support customized formulation development, but the number of strains available should not be the only selection criterion.

The important considerations are the identity, quality, suitability, and evidence associated with each proposed strain.

Ask whether the manufacturer develops and maintains its own strains, sources strains from qualified suppliers, or combines internally developed strains with externally sourced ingredients.

The supplier should also explain how it manages strain authentication, supplier qualification, incoming-material checks, and traceability.

Research-led formulation development

A scientifically capable manufacturer should be able to explain the rationale behind a proposed blend.

This includes identifying the intended formulation objective, reviewing relevant evidence, considering strain characteristics, assessing compatibility, and selecting appropriate quality specifications.

The manufacturer should distinguish between established evidence, preliminary laboratory observations, and hypotheses that require further research.

A review of probiotic product selection highlights the importance of matching specific strains and formulations to the intended application rather than assuming that all probiotic products are equivalent [3].

For buyers, this distinction helps prevent the purchase of formulations whose commercial claims exceed their available scientific support.

Assess the Scientific Evidence Supporting the Proposed Blend

Scientific evidence should be a central component of the supplier evaluation process.

A manufacturer may offer a large number of strains, a high declared CFU count, or a complex blend. None of these characteristics alone establishes that the finished formulation provides a particular benefit.

Review evidence at the strain level

Where health-related benefits are part of the intended product positioning, examine the available evidence for the specific strain or combination of strains.

Relevant evidence may include:

  • Randomized controlled human trials

  • Systematic reviews and meta-analyses

  • Published clinical studies

  • Safety assessments

  • Mechanistic research

  • Relevant observational studies

These sources do not carry equal evidentiary weight. Laboratory studies may support a biological hypothesis, but they do not independently establish a clinical benefit in humans.

A systematic review examining single-strain probiotics and multi-strain mixtures found that the relative effectiveness of these approaches varied by indication. The review concluded that formulation selection should be based on evidence for the relevant application rather than the number of strains in the product [4].

Evaluate clinical-trial relevance

When reviewing a study, ask:

  • Was the specific strain identified?

  • Was the studied formulation the same as, or comparable to, the proposed blend?

  • What dose was administered?

  • What population was studied?

  • How long did the study last?

  • Which outcomes were measured?

  • Was the study adequately designed?

  • Are the results relevant to the intended market and product claims?

A clinical trial involving a single strain does not automatically validate a different multi-strain formulation containing that strain.

Similarly, evidence from a specialized population may not establish the same outcome in the general population.

The evidence-based guide by Goodman and colleagues emphasizes the importance of evaluating strain, indication, dosage form, dose, manufacturing quality, and shelf life when selecting probiotic products [3].

Understand Single-Strain and Multi-Strain Probiotic Formulations

Probiotic blends may contain two strains or many different microorganisms. The most appropriate composition depends on the intended application, available evidence, technical compatibility, and product specifications.

Is a multi-strain blend always better?

No. Increasing the number of strains does not automatically increase product quality or effectiveness.

A multi-strain formulation may be appropriate when the combination has a clear scientific or technical rationale. However, a well-characterized single-strain product may be preferable when it has stronger evidence for the intended application or offers advantages in stability, manufacturing, or cost.

A systematic review comparing single-strain probiotics with multi-strain mixtures found that many comparisons did not demonstrate superior effectiveness for the mixtures. The findings support evidence-led selection rather than choosing formulations simply because they contain more strains [4].

Evaluate compatibility

A manufacturer should assess whether the selected strains can be combined into a stable, consistent product.

Potential considerations include:

  • Differences in moisture sensitivity

  • Oxygen sensitivity

  • Temperature sensitivity

  • Storage requirements

  • Ingredient interactions

  • Differences in viable-count decline

  • Compatibility with excipients and carriers

  • Suitability for the intended dosage form

Compatibility should be established through appropriate technical evaluation. It should not be assumed simply because the strains belong to commonly used probiotic species.

Evaluate the contribution of each strain

For a customized blend, ask why each strain has been included.

The manufacturer should be able to explain whether a strain was selected because of relevant clinical evidence, a defined formulation objective, technological suitability, or another documented reason.

The answer should distinguish scientific evidence from a proposed mechanism or development hypothesis.

Assess evidence for the complete combination

Evidence for the individual components can help inform formulation development, but it does not necessarily establish the performance of the complete blend.

The final formulation may differ from the studied products in strain composition, relative proportions, total dose, delivery format, or storage conditions.

For this reason, the evidence supporting each component and the evidence supporting the complete formulation should be documented separately.

Bifidobacterium lactis probiotic powder CFU specification
Confirm whether a declared CFU count applies at release or at the end of shelf life.

Verify CFU Specifications and Viability Throughout Shelf Life

Colony-forming units, commonly abbreviated as CFU, are used to express the number of viable microorganisms capable of forming colonies under specified test conditions.

CFU is an important purchasing specification for probiotic ingredients. However, buyers should understand precisely what the declared count represents.

Understand the difference between raw-material potency and finished-product potency

A manufacturer may specify CFU per gram of bulk powder, CFU per serving, or CFU per finished capsule.

These specifications are not interchangeable.

For example, a bulk powder with a specified potency may be used at a particular inclusion rate to achieve a target CFU per serving. The calculation must account for the ingredient potency, the amount added, the manufacturing process, and any expected viability loss.

A qualified supplier should clearly identify whether the specification applies to:

  • The bulk ingredient at release

  • The formulated blend at release

  • The finished dosage form at release

  • The finished product at the end of shelf life

End-of-shelf-life viability

A product that meets its CFU specification when manufactured may not maintain the same viable count throughout storage.

The probiotic definition and qualification framework described by Binda and colleagues emphasizes that viable microorganisms should remain present at an efficacious level throughout the product's shelf life [1].

For commercial production, ask the manufacturer to explain how the proposed formulation will meet its declared specification over the intended shelf life.

Overages and potency targets

Manufacturers may use a justified initial potency target or overage to compensate for expected viability losses.

However, overages should be supported by stability data and a documented formulation rationale.

An arbitrary increase in the starting CFU count is not a substitute for understanding degradation behaviour.

Ask the supplier:

  • What is the release specification?

  • What is the minimum potency guaranteed at expiry?

  • What stability data support the proposed shelf life?

  • How is potency measured?

  • What storage conditions apply?

  • Is the stability data relevant to the proposed formulation and packaging?

CFU testing methodology

Ask which analytical method is used and whether the method is appropriate for the organisms being measured.

For multi-strain products, a total viable count may not establish the viable count of each individual strain. Where individual strain counts are required, the manufacturer should explain how those measurements are performed and validated.

The test method, sample preparation, incubation conditions, reporting basis, and limitations should be documented.

Purchasing principle: Specify the required CFU per gram or per serving, the applicable test method, the release limit, and the end-of-shelf-life requirement in the product specification.

Examine Manufacturing Infrastructure and Process Controls

The quality of a probiotic blend depends on the controls applied throughout manufacturing, not merely on the final product's appearance or declared potency.

The manufacturing partner should demonstrate that it can produce the specified formulation consistently and traceably.

Manufacturing process

Depending on the supplier's business model and capabilities, probiotic production may involve culture preparation, fermentation, harvesting, concentration, drying, blending, testing, and packaging.

Some suppliers manufacture microbial biomass themselves. Others purchase qualified probiotic powders and blend them into finished bulk ingredients.

Both models can be appropriate, provided the company accurately describes its capabilities and maintains suitable controls.

Ask whether the supplier performs the following activities in-house or through qualified external partners:

  • Strain development and maintenance

  • Fermentation

  • Drying and stabilization

  • Ingredient blending

  • Quality-control testing

  • Packaging

  • Stability studies

  • Finished-product release

The purpose is not to insist that every activity must take place at one facility. It is to understand responsibility, traceability, and quality oversight throughout the supply chain.

Process consistency

A supplier should have documented procedures for critical manufacturing activities.

These may include material identification, weighing, blending, environmental monitoring where appropriate, equipment cleaning, in-process checks, deviation management, and batch release.

The precise controls depend on the product, process, facility, and applicable regulations.

Ask how the manufacturer controls variation between batches and investigates results that fall outside established specifications.

Cross-contamination prevention

Because probiotic manufacturing involves microbial materials, the supplier should have a documented contamination-control strategy.

Relevant controls may include:

  • Appropriate facility and equipment design

  • Segregation based on risk assessment

  • Validated or otherwise justified cleaning procedures

  • Personnel hygiene and training

  • Environmental monitoring where appropriate

  • Raw-material and finished-product testing

  • Documented deviation investigations

  • Traceability and recall procedures

The supplier should explain how it evaluates risks from other microbial materials processed at the same site.

A buyer should not rely solely on a statement that a facility is “dedicated” or “contamination-free.” Ask for the relevant documented controls and their scope.

Manufacturing quality systems

Ask the supplier which quality-management systems and certifications apply to the specific facility and product.

Potentially relevant systems include good manufacturing practices, applicable food-safety management systems, and quality-management certifications.

Verify the certificate issuer, scope, site address, validity, and product relevance. A certificate covering one facility or activity should not be assumed to cover every manufacturing operation conducted by the company.

Review Quality Assurance and Documentation

A professional bulk probiotic supplier should provide a clear, consistent documentation package.

Documentation supports incoming inspection, regulatory review, product release, customer audits, and ongoing supplier qualification.

Certificate of Analysis

A Certificate of Analysis (CoA) should identify the tested material and report the results of the specified tests.

Depending on the ingredient and customer requirements, a CoA may include:

  • Product name and code

  • Batch or lot number

  • Test methods

  • Identity results

  • Viable count or potency

  • Relevant microbiological limits

  • Physical or chemical specifications, where applicable

  • Manufacture or retest information

  • Storage requirements

  • Release status

The CoA should be traceable to the supplied lot.

Ask whether the results are generated by the manufacturer's laboratory, an external laboratory, or a combination of both. Independent testing can provide additional assurance where justified, but its value depends on laboratory competence, test suitability, and the scope of testing.

Additional technical documents

Depending on the intended use and destination market, request:

  • Technical Data Sheet

  • Product Specification

  • Strain identification documentation

  • Safety information

  • Allergen statement

  • GMO statement, where relevant

  • Residual solvent or contaminant information, where applicable

  • Heavy-metal results, where applicable

  • Microbiological specifications

  • Stability data

  • Packaging specification

  • Storage and handling instructions

  • Country-of-origin information

  • Applicable regulatory declarations

Not every document is required for every ingredient. The correct package depends on the product category, market, customer requirements, and applicable law.

Traceability

The manufacturer should be able to trace a supplied lot to relevant raw materials, manufacturing records, testing results, and release documentation.

Ask how the supplier manages lot identification, retained samples, complaints, deviations, and recalls.

A robust traceability system helps the customer investigate quality concerns and identify affected products efficiently.

Supplier audit

For strategic or high-volume sourcing, consider conducting a supplier audit or commissioning a qualified third party to do so.

The audit may review:

  • Quality-management procedures

  • Manufacturing controls

  • Laboratory capability

  • Documentation systems

  • Storage conditions

  • Supplier qualification

  • Change control

  • Complaint handling

  • Recall procedures

  • Business continuity arrangements

The audit scope should be proportional to the ingredient's risk, the intended application, and the commercial relationship.

Bacillus coagulans probiotic powder stability and packaging
Stability, packaging and storage needs differ from strain to strain.

Evaluate Stability, Packaging, and Storage Requirements

Probiotic stability is a key determinant of product quality.

Viability can be influenced by temperature, moisture, oxygen exposure, formulation composition, packaging, and storage conditions. These factors should be evaluated for the actual product rather than assumed from general information.

Moisture management

Many probiotic powders require controlled moisture conditions.

Ask the supplier about the material's moisture specification, recommended handling conditions, and sensitivity to exposure during manufacturing and packaging.

Where appropriate, assess whether the packaging provides adequate protection against moisture ingress.

Oxygen exposure

Some microorganisms are particularly sensitive to oxygen exposure. The impact depends on the strain, formulation, processing conditions, and packaging system.

A manufacturer should be able to explain the relevant controls and provide supporting stability information where required.

Temperature management

Confirm the recommended storage temperature and whether the material requires refrigerated or controlled-temperature storage.

Do not assume that all probiotic ingredients require refrigeration, or that all can be stored at room temperature.

Storage requirements should be based on product-specific data and the supplier's validated or otherwise adequately supported specifications.

Packaging options

Depending on the ingredient and quantity, packaging may include sealed barrier bags, lined drums, or other suitable food-contact packaging.

The manufacturer should specify:

  • Pack size

  • Packaging material

  • Moisture and oxygen protection, where relevant

  • Storage instructions

  • Handling requirements after opening

  • Shelf life or retest period

  • Transport conditions

Stability studies

Ask whether stability data correspond to the actual ingredient or formulation being purchased.

Evidence from a different blend, packaging format, or storage condition may not be directly transferable.

A useful stability package should describe the tested material, packaging, storage conditions, test intervals, analytical methods, and acceptance criteria.

Confirm Regulatory Readiness for Your Target Market

Regulatory suitability is a critical part of probiotic ingredient sourcing.

The fact that a microorganism is used in a supplement in one country does not automatically mean it is permitted for every product category in every market.

United States

For products intended for the United States, determine the relevant regulatory classification and requirements for the finished product and its ingredients.

Dietary supplement manufacturers should assess applicable obligations involving ingredient status, manufacturing controls, labeling, and product claims.

The FDA provides information on dietary supplements and current good manufacturing practices for dietary supplements [11].

The manufacturer's documentation can support this review, but the finished-product company remains responsible for determining its own legal obligations.

European Union

For products intended for the European Union, assess the applicable food or supplement framework, ingredient status, safety requirements, labeling, and permissible claims.

EFSA's Qualified Presumption of Safety framework is a safety-assessment approach for microorganisms within its scope. QPS status does not automatically authorize a finished product or establish that every strain or formulation is suitable for every application [5].

Where a product depends on a specific authorized health claim or ingredient status, the relevant regulatory position should be checked separately.

United Kingdom

For the United Kingdom, determine the applicable requirements based on the product classification, ingredient composition, labeling, claims, and intended route to market.

Do not assume that regulatory conclusions applicable to the European Union automatically resolve every UK requirement.

India and other export markets

For India, review the applicable requirements of the Food Safety and Standards Authority of India and the relevant product category.

For exports to the Gulf region and other international destinations, assess local registration, ingredient acceptability, labelling, import documentation, and any product-specific requirements.

Regulatory suitability should be confirmed for the actual formulation and destination market.

Claims substantiation

Marketing statements should reflect the evidence available and comply with applicable regulations.

Avoid assuming that laboratory findings, animal studies, or research on a different strain justify a health claim for the finished product.

For regulatory assessment, consult the relevant official authority and qualified regulatory professionals.

Lactobacillus plantarum powder for custom probiotic blend formulation
Custom probiotic blends combine selected strains, carriers and potency targets.

Assess Custom Formulation and Product Development Capabilities

Some buyers need a standard probiotic blend. Others require a formulation tailored to a particular brand, dosage form, market, or product specification.

A capable development partner should have a defined process for translating the customer's brief into a manufacturable formulation.

Strain selection

The process begins by identifying suitable candidate strains based on the intended application, available evidence, safety considerations, technical requirements, and regulatory constraints.

The manufacturer should explain the selection rationale and identify any limitations or unresolved questions.

Blend composition

The supplier should specify the composition of the proposed blend, including strain identities, proportions where disclosed, potency targets, and other relevant ingredients.

For proprietary formulations, the parties should agree on what technical information can be disclosed and how confidential information will be protected.

Excipients and carriers

Carriers and excipients can influence powder handling, blending, processing, and stability.

Ask the manufacturer to identify the relevant ingredients and explain their intended functions.

Confirm that the proposed composition is suitable for the target product, customer requirements, and applicable market regulations.

Prototype and pilot evaluation

Before committing to large-scale production, consider a laboratory sample or pilot batch.

Depending on the project, evaluation may include:

  • Blend uniformity

  • Viable count

  • Flow properties

  • Moisture-related characteristics

  • Capsule or sachet filling performance

  • Packaging compatibility

  • Preliminary stability

  • Compatibility with other formula ingredients

The appropriate tests depend on the formulation and intended manufacturing process.

Scale-up and commercial production

A successful laboratory formulation does not automatically guarantee identical performance at commercial scale.

The manufacturer should document relevant scale-up considerations, acceptance criteria, and any changes required before routine production.

For customers planning repeated orders, the supplier should also define change-control procedures so that material changes are reviewed and communicated appropriately.

Evaluate the Manufacturer's Commercial Capabilities

Technical quality is essential, but the supplier must also support the customer's commercial objectives.

Minimum order quantity

Ask for the minimum order quantity for standard and customized blends.

The minimum may depend on ingredient availability, blending requirements, packaging, testing, and production scheduling.

For a new product, a smaller pilot quantity can reduce inventory exposure while the customer evaluates market demand.

Production capacity

Confirm whether the supplier can support the forecasted volume and delivery schedule.

Ask about standard lead times, seasonal constraints, production planning, and the ability to accommodate repeat orders.

Capacity claims should be evaluated against the specific product and production line rather than the manufacturer's total facility capacity alone.

Pricing structure

Request a quotation that clearly states:

  • Price per kilogram or other agreed unit

  • Minimum order quantity

  • Packaging costs

  • Testing charges

  • Custom formulation charges

  • Sample costs

  • Freight terms

  • Payment terms

  • Quotation validity

  • Applicable taxes or duties

A low initial quotation may not represent the lowest total cost if additional testing, special packaging, storage, or logistics charges apply.

Lead time and supply continuity

Ask the supplier to explain its normal production and delivery timeline.

For critical ingredients, evaluate business continuity, backup sourcing where appropriate, raw-material availability, and the process for communicating potential delays.

Technical support

A strong B2B partner should provide appropriate support during specification development, sample evaluation, troubleshooting, and repeat production.

The precise support available may include formulation consultation, documentation review, stability discussions, or manufacturing guidance.

Clarify what is included in the commercial agreement and what may incur additional charges.

Compare Suppliers Using a Structured Evaluation Scorecard

A structured scorecard makes supplier selection more objective and helps procurement teams document their decisions.

The following is an illustrative framework. Buyers can adjust the weighting to reflect their product's risk, market, and technical complexity.

Evaluation criterion

Suggested weight

Strain identification and traceability

10%

Scientific evidence and formulation rationale

15%

Quality systems and manufacturing controls

15%

CFU specification and viability management

15%

Stability and packaging support

10%

Documentation and regulatory support

10%

Custom formulation and technical capability

10%

Supply capacity and lead time

5%

Pricing and total cost

5%

Communication and customer support

5%

Total

100%

Score each supplier against the same criteria using a defined rating scale, such as 1 to 5.

A high score should not override a critical failure. For example, an ingredient that cannot meet a mandatory safety or regulatory requirement should not be approved simply because its price and lead time are attractive.

Use the scorecard alongside documentation review, sample testing, and supplier qualification.

Red Flags to Watch for When Selecting a Probiotic Manufacturer

Buyers should investigate warning signs before entering a long-term supply agreement.

Red flag 1: No clear strain identification

A supplier that cannot provide adequate information about strain identity may make scientific evaluation and traceability difficult.

Red flag 2: Unsupported health claims

Claims that a formulation guarantees a particular clinical outcome should be scrutinized, especially when the supplier cannot provide relevant evidence.

Red flag 3: No clear CFU basis

A quotation that states a large CFU number without specifying the unit, test method, or shelf-life basis is incomplete.

Red flag 4: Missing stability information

If the supplier proposes a long shelf life without appropriate supporting information, ask for clarification before approving the specification.

Red flag 5: Incomplete batch documentation

Missing or inconsistent lot numbers, specifications, test results, or traceability information can create quality-management problems.

Red flag 6: Unclear manufacturing responsibility

A company may source ingredients from third parties and still provide a legitimate blending service. However, it should clearly explain its role and the controls applied to external suppliers.

Red flag 7: Unverified certifications

Check whether certificates are authentic, current, and applicable to the specific manufacturing site and activity.

Red flag 8: No defined change-control process

Changes to strains, suppliers, potency, carriers, manufacturing methods, or packaging may affect product quality. Customers should understand how such changes are assessed and communicated.

Red flag 9: Unrealistic pricing

An unusually low quotation should prompt a review of the specification, potency basis, testing scope, packaging, and commercial terms.

Red flag 10: Poor technical communication

A manufacturer should be able to explain its specifications and provide appropriate supporting documents. Repeatedly vague or contradictory responses may indicate weaknesses in technical or quality management.

Questions to Ask Before Placing a Bulk Order

Before approving a probiotic blend manufacturer, ask the supplier the following questions.

Product identity and composition

  • What are the complete strain designations in the blend?

  • What is the declared potency of each ingredient or of the final blend?

  • Is the composition standardized across batches?

  • Are carriers or other excipients included?

Scientific evidence

  • What evidence supports the proposed formulation?

  • Which studies relate to the exact strains?

  • Is the complete blend supported by relevant studies?

  • What limitations should be considered when interpreting the evidence?

Quality and manufacturing

  • How is strain identity confirmed?

  • What quality systems apply to the manufacturing site?

  • Which tests are included in the batch CoA?

  • How are microbial contamination risks controlled?

  • How is batch-to-batch consistency evaluated?

Stability and packaging

  • What is the CFU specification at release?

  • What potency is guaranteed at the end of shelf life?

  • What stability data support the proposed shelf life?

  • What are the storage and transport requirements?

  • What packaging options are available?

Regulatory and commercial

  • What documentation is available for the target market?

  • What are the MOQ, lead time, and pricing terms?

  • Can the manufacturer supply a development sample?

  • How are changes to the formulation communicated?

  • What support is available for troubleshooting and repeat orders?

  • What is the process for complaints, investigations, and recalls?

The supplier's responses should be evaluated alongside the supporting documentation rather than accepted as a substitute for it.

How to Request a Probiotic Blend Quotation

A well-prepared request for quotation helps manufacturers provide accurate and comparable offers.

Your RFQ should include the following information.

Product brief

  • Product category and intended application

  • Target market or countries

  • Proposed strains, if already selected

  • Desired strain count or formulation approach

  • Required CFU per gram, capsule, or serving

  • Intended dosage form

  • Required shelf life

  • Expected annual volume

Technical requirements

  • Required identity and potency tests

  • Microbiological specifications

  • Applicable contaminant limits

  • Stability requirements

  • Packaging preferences

  • Storage and transport conditions

  • Documentation requirements

Commercial requirements

  • Requested sample quantity

  • Initial order quantity

  • Forecast for subsequent orders

  • Delivery destination

  • Preferred delivery terms

  • Required delivery schedule

  • Payment terms

  • Whether the project requires a custom formulation

If the formulation is still being developed, state that clearly. A manufacturer may be able to recommend a technically appropriate starting point after reviewing the intended application and constraints.

Avoid specifying a formulation solely on the basis of a desired CFU number. The ingredient composition, potency basis, scientific rationale, and stability requirements must also be considered.

Work With Swiss Medicare Probiotics

Swiss Medicare Probiotics manufactures probiotic strains and custom probiotic blends in bulk for supplement, functional food and private-label brands. Explore our probiotic formulation services, or contact our team to request specifications, documentation and a quotation for your project.

Related Reading

Frequently Asked Questions

1. What should I look for in a probiotic blend manufacturer?

Look for a supplier that can demonstrate strain identification, appropriate safety controls, scientific and technical competence, documented manufacturing processes, suitable CFU specifications, stability support, traceability, and reliable commercial service. The relative importance of each criterion depends on the intended product and market. Scientific guidance identifies characterization, safety, relevant evidence, and viability throughout shelf life as key considerations when qualifying probiotic microorganisms [1].

Not necessarily. The best choice depends on the intended application and the evidence supporting the specific strain or combination. A systematic review found that multi-strain mixtures were not consistently more effective than single-strain products across the indications examined [4].

CFU stands for colony-forming units. It is a measure of viable microorganisms capable of forming colonies under specified test conditions. Buyers should confirm whether the declared CFU applies to the bulk ingredient, the finished product at release, or the product at the end of shelf life.

The specification should clearly define the required potency and the point at which it applies. For a product intended to deliver viable probiotics throughout its shelf life, the manufacturer should provide appropriate evidence that the specified viable count can be maintained under the stated storage conditions [1].

Depending on the product and market, relevant documents may include a Certificate of Analysis, Technical Data Sheet, product specification, strain identity information, safety documentation, microbiological test results, stability information, storage instructions, and applicable regulatory declarations.

Search PubMed and Europe PMC using the organism's full strain designation and the intended application. Review the study population, dose, formulation, outcomes, and limitations. For clinical studies, ClinicalTrials.gov can help identify registered trials, but registration alone does not establish efficacy.

Not automatically. Probiotic effects can be strain-specific and indication-specific. Research reviews have identified meaningful differences in the evidence supporting individual strains and their applications [2].

An ingredient manufacturer may produce microbial biomass or probiotic powders, while a blender may combine qualified ingredients into a specified formulation. Some businesses perform both activities, whereas others outsource parts of the process. Buyers should confirm which activities occur at each site and how quality responsibilities are managed.

Yes, depending on its technical capabilities and ingredient access. Custom development may involve strain selection, blend composition, potency targets, carrier selection, dosage-form compatibility, stability evaluation, and documentation. The manufacturer should explain which stages are supported in-house and which depend on external partners.

There is no universal MOQ. It depends on the supplier, formulation, ingredient availability, packaging, production process, and testing requirements. Request separate quotations for samples, pilot quantities, and commercial production where available.

Compare equivalent specifications. Confirm the strain composition, potency basis, testing scope, packaging, shelf life, documentation, MOQ, delivery terms, and payment conditions. A lower price per kilogram may not represent a better commercial value if the material does not meet the required specification.

No. Storage requirements vary according to the strains, formulation, manufacturing process, packaging, and stability data. Follow the product-specific storage instructions and do not assume that one storage condition applies to every probiotic powder.

Check the product identity, batch number, specification, test methods, reported results, potency basis, relevant microbiological limits, release status, and any applicable storage or retest information. Confirm that the document corresponds to the exact lot being supplied.

No. QPS is a safety-assessment approach for microorganisms within its scope. EFSA explains that QPS status does not automatically lead to market authorization, and product-specific regulatory requirements may still apply [5].

Not automatically. The study must be relevant to the strain, formulation, dose, population, outcome, and intended claim. The finished product's claims must also comply with the applicable market's rules.

Ask about facility controls, cleaning procedures, segregation where appropriate, personnel training, environmental monitoring where applicable, testing, traceability, and deviation management. Request documentation relevant to the actual product and manufacturing site.

Potentially, but suitability depends on the microorganisms, beverage composition, processing conditions, storage environment, packaging, and required shelf life. The manufacturer should assess compatibility and viability for the specific beverage rather than relying on general claims about probiotic ingredients.

The timeline varies with formulation complexity, ingredient availability, testing requirements, regulatory review, and the number of development iterations. Request a project schedule that separates formulation, sampling, evaluation, documentation, and commercial scale-up.

There is no single factor that applies to every project. However, the supplier must be capable of meeting the required product specification consistently and providing credible evidence of identity, quality, safety, stability, and traceability. Price and delivery performance should be assessed after mandatory technical and regulatory requirements are satisfied.

Scientific References

The following references correspond to the numbered citations used throughout the article.

[1] Binda S, Hill C, Johansen E, et al. Criteria to Qualify Microorganisms as “Probiotic” in Foods and Dietary Supplements. Frontiers in Microbiology. 2020;11:1662. PubMed | Full text on PubMed Central

[2] McFarland LV, Evans CT, Goldstein EJC. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Frontiers in Medicine. 2018. PubMed

[3] Goodman C, Keating G, Georgousopoulou E, et al. Choosing an Appropriate Probiotic Product for Your Patient: An Evidence-Based Practical Guide. PubMed | Europe PMC

[4] McFarland LV. Efficacy of Single-Strain Probiotics Versus Multi-Strain Mixtures: Systematic Review of Strain and Disease Specificity. Digestive Diseases and Sciences. 2021;66:694–704. PubMed

[5] European Food Safety Authority (EFSA). Qualified Presumption of Safety (QPS): Assessment of Microorganisms Used in the Food Chain. EFSA guidance | EFSA QPS topic page

[6] European Food Safety Authority (EFSA). Health Claims: Scientific Assessment and Regulatory Information. EFSA health claims

[7] U.S. National Library of Medicine. PubMed: Biomedical Literature Database. PubMed

[8] Europe PMC. Biomedical Literature Database. Europe PMC

[9] ClinicalTrials.gov. Clinical Study Registry and Results Database. ClinicalTrials.gov

[10] ScienceDirect. Scientific Literature Search. ScienceDirect

[11] U.S. Food and Drug Administration (FDA). Dietary Supplements: Regulatory and Consumer Information. FDA

[12] U.S. Food and Drug Administration (FDA). Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. FDA CGMP guidance

 
 
 

Comments


bottom of page